Century Therapeutics, Inc. Increase (Decrease) in Deferred Revenue
Century Therapeutics, Inc. (IPSC) reported Increase (Decrease) in Deferred Revenue of -$109.16 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2026-08-12
- Century Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2025-12-31 was $0.00.
- Century Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2025-09-30 was $0.00.
- Century Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2025-06-30 was $0.00.
- Century Therapeutics, Inc. increase (decrease) in deferred revenue for the quarter ending 2025-03-31 was -$109.16M.
- Century Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2025 was -$109.16M.
- Century Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2024 was -$6.59M.
- Century Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2023 was -$2.23M, a 101.89% decline from fiscal 2022.
- Century Therapeutics, Inc. increase (decrease) in deferred revenue for fiscal 2022 was $117.99M.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $0.00 derived: sum of 3 quarters · filed 2026-08-12 | -$109.16M 10-K · filed 2026-03-12 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2026-08-12 | -$109.16M 10-Q · filed 2025-11-13 | -$113.34M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$109.16M 10-Q · filed 2026-08-12 | -$113.34M derived: sum of 3 quarters · filed 2026-08-12 | -$114.13M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$109.16M 10-Q · filed 2026-05-13 | -$113.34M derived: sum of 2 quarters · filed 2026-05-13 | -$114.13M derived: sum of 3 quarters · filed 2026-05-13 | -$114.90M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$4.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$4.96M derived: sum of 2 quarters · filed 2026-03-12 | -$5.73M derived: sum of 3 quarters · filed 2026-03-12 | -$6.59M 10-K · filed 2026-03-12 |
| 2024-09-30 | -$791.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$1.56M derived: sum of 2 quarters · filed 2025-11-13 | -$2.42M 10-Q · filed 2025-11-13 | -$2.68M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$770.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$1.63M 10-Q · filed 2025-08-14 | -$1.89M derived: sum of 3 quarters · filed 2025-08-14 | -$2.04M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$855.00K 10-Q · filed 2025-05-15 | -$1.12M derived: sum of 2 quarters · filed 2025-05-15 | -$1.27M derived: sum of 3 quarters · filed 2025-05-15 | -$1.37M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$268.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | -$416.00K derived: sum of 2 quarters · filed 2025-03-19 | -$515.00K derived: sum of 3 quarters · filed 2025-03-19 | -$2.23M 10-K · filed 2025-03-19 |
| 2023-09-30 | -$148.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$247.00K derived: sum of 2 quarters · filed 2024-11-05 | -$1.97M 10-Q · filed 2024-11-05 | -$2.49M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | -$99.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$1.82M 10-Q · filed 2024-08-08 | -$2.34M derived: sum of 3 quarters · filed 2024-08-08 | -$4.56M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$1.72M 10-Q · filed 2024-05-09 | -$2.24M derived: sum of 2 quarters · filed 2024-05-09 | -$4.46M derived: sum of 3 quarters · filed 2024-05-09 | -$5.86M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$521.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$2.75M derived: sum of 2 quarters · filed 2024-03-14 | -$4.14M derived: sum of 3 quarters · filed 2024-03-14 | $117.99M 10-K · filed 2024-03-14 |
| 2022-09-30 | -$2.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$3.62M derived: sum of 2 quarters · filed 2023-11-09 | $118.51M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | -$1.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $120.73M 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | $122.13M 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |